证据评分
健康相关的生活质量:有高质量证据表明,与安慰剂相比非麦角类多巴胺激动剂可改善 RLS 患者的健康相关生活质量。[21]Talati R, Phung OJ, Mather J, et al. Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome. Ann Pharmacother. 2009;43:813-821.http://www.ncbi.nlm.nih.gov/pubmed/19401472?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
健康相关的生活质量:有高质量证据表明,与安慰剂相比非麦角类多巴胺激动剂可改善 RLS 患者的健康相关生活质量。[21]Talati R, Phung OJ, Mather J, et al. Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome. Ann Pharmacother. 2009;43:813-821.http://www.ncbi.nlm.nih.gov/pubmed/19401472?tool=bestpractice.com
症状严重程度:有高质量证据表明,与安慰剂相比非麦角类多巴胺激动剂可降低 RLS 症状的严重程度。[22]Baker WL, White CM, Coleman CI. Effect of nonergot dopamine agonists on symptoms of restless legs syndrome. Ann Fam Med. 2008;6:253-262.http://www.annfammed.org/cgi/content/full/6/3/253http://www.ncbi.nlm.nih.gov/pubmed/18474889?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
症状严重程度:有高质量证据表明,与安慰剂相比非麦角类多巴胺激动剂可降低 RLS 症状的严重程度。[22]Baker WL, White CM, Coleman CI. Effect of nonergot dopamine agonists on symptoms of restless legs syndrome. Ann Fam Med. 2008;6:253-262.http://www.annfammed.org/cgi/content/full/6/3/253http://www.ncbi.nlm.nih.gov/pubmed/18474889?tool=bestpractice.com